Q-lineas vd Jonas Jarvius kommenterar Q3-rapporten och den fortsatta utvecklingen av ASTar. Jonas berättar även om bakgrunden till den försenade studiestarten och den positiva återkopplingen från FDA. Intervjun spelades in den 8:e november.
You need to be a Redeye member to access this content
Become a member to:
Access all our extensive research on 100+ Nordic Tech and Life Science companies
Make smarter investment decisions with the guidance of our experienced analysts
Receive exciting offers to participate in IPO’s and other transactions
By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions